Literature DB >> 24752550

Cyanidin-3-O-β-glucoside inhibits lipopolysaccharide-induced inflammatory response in mouse mastitis model.

Yunhe Fu1, Zhengkai Wei1, Ershun Zhou1, Naisheng Zhang1, Zhengtao Yang1.   

Abstract

Cyanidin-3-O-β-glucoside (C3G) (CAS number 7084-24-4), a typical anthocyanin pigment that exists in the human diet, has been reported to have anti-inflammatory properties. However, the effect of C3G on lipopolysaccharide (LPS)-induced mastitis and the molecular mechanisms have not been investigated. In this study, we detected the protective effects of C3G on a LPS-induced mouse mastitis model and investigated the molecular mechanisms in LPS-stimulated mouse mammary epithelial cells (MMECs). Our results showed that C3G could attenuate mammary histopathologic changes and myeloperoxidase activity, and inhibit TNF-α, interleukin (IL)-1β, and IL-6 production caused by LPS. Meanwhile, C3G dose-dependently inhibited TNF-α and IL-6 in LPS-stimulated MMECs. C3G suppressed LPS-induced nuclear factor-κB (NF-κB) and interferon regulatory factor 3 (IRF3) activation. Furthermore, C3G disrupted the formation of lipid rafts by depleting cholesterol. Moreover, C3G activated liver X receptor (LXR)-ABCG1-dependent cholesterol efflux. Knockdown of LXRα abrogated the anti-inflammatory effects of C3G. In conclusion, C3G has a protective effect on LPS-induced mastitis. The promising anti-inflammatory mechanisms of C3G are associated with upregulation of the LXRα-ABCG1 pathway which result in disrupting lipid rafts by depleting cholesterol, thereby suppressing toll-like receptor 4-mediated NF-κB and IRF3 signaling pathways induced by LPS.
Copyright © 2014 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  ATP binding cassette transporter G1; interferon regulatory factor 3; lipid raft; liver X receptor; nuclear factor-κB; toll-like receptor 4

Mesh:

Substances:

Year:  2014        PMID: 24752550      PMCID: PMC4031942          DOI: 10.1194/jlr.M047340

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  32 in total

1.  Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta.

Authors:  B A Janowski; M J Grogan; S A Jones; G B Wisely; S A Kliewer; E J Corey; D J Mangelsdorf
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

2.  Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product.

Authors:  K Hoshino; O Takeuchi; T Kawai; H Sanjo; T Ogawa; Y Takeda; K Takeda; S Akira
Journal:  J Immunol       Date:  1999-04-01       Impact factor: 5.422

3.  Lipopolysaccharide and lipoteichoic acid induce different innate immune responses in bovine mammary epithelial cells.

Authors:  Ylva Strandberg; Christian Gray; Tony Vuocolo; Laurelea Donaldson; Mary Broadway; Ross Tellam
Journal:  Cytokine       Date:  2005-07-07       Impact factor: 3.861

4.  Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol.

Authors:  Xuewei Zhu; John S Owen; Martha D Wilson; Haitao Li; Gary L Griffiths; Michael J Thomas; Elizabeth M Hiltbold; Michael B Fessler; John S Parks
Journal:  J Lipid Res       Date:  2010-07-21       Impact factor: 5.922

5.  ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I.

Authors:  Ingrid C Gelissen; Matthew Harris; Kerry-Anne Rye; Carmel Quinn; Andrew J Brown; Maaike Kockx; Sian Cartland; Mathana Packianathan; Leonard Kritharides; Wendy Jessup
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-12-15       Impact factor: 8.311

Review 6.  TLR4, ethanol, and lipid rafts: a new mechanism of ethanol action with implications for other receptor-mediated effects.

Authors:  Gyongyi Szabo; Angela Dolganiuc; Qun Dai; Stephen B Pruett
Journal:  J Immunol       Date:  2007-02-01       Impact factor: 5.422

7.  Emodin ameliorates lipopolysaccharide-induced mastitis in mice by inhibiting activation of NF-κB and MAPKs signal pathways.

Authors:  Depeng Li; Naisheng Zhang; Yongguo Cao; Wen Zhang; Gaoli Su; Yong Sun; Zhicheng Liu; Fengyang Li; Dejie Liang; Bo Liu; Mengyao Guo; Yunhe Fu; Xichen Zhang; Zhengtao Yang
Journal:  Eur J Pharmacol       Date:  2013-03-13       Impact factor: 4.432

8.  Lipid rafts regulate ethanol-induced activation of TLR4 signaling in murine macrophages.

Authors:  Sara Fernandez-Lizarbe; Maria Pascual; M Soledad Gascon; Ana Blanco; Consuelo Guerri
Journal:  Mol Immunol       Date:  2007-12-03       Impact factor: 4.407

9.  Surfactant lipids regulate LPS-induced interleukin-8 production in A549 lung epithelial cells by inhibiting translocation of TLR4 into lipid raft domains.

Authors:  Wondwossen Abate; Abdulaziz A Alghaithy; Joan Parton; Kenneth P Jones; Simon K Jackson
Journal:  J Lipid Res       Date:  2009-08-01       Impact factor: 5.922

Review 10.  Prevalence, incidence and risk factors of heifer mastitis.

Authors:  L K Fox
Journal:  Vet Microbiol       Date:  2008-09-11       Impact factor: 3.293

View more
  17 in total

1.  Anti-Inflammatory Effects of Taraxasterol on LPS-Stimulated Human Umbilical Vein Endothelial Cells.

Authors:  Feng Zheng; Xiaomeng Dong; Xiangzhu Meng
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

Review 2.  Role of Liver X Receptor in Mastitis Therapy and Regulation of Milk Fat Synthesis.

Authors:  Xiaoyu Hu; Naisheng Zhang; Yunhe Fu
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-07-31       Impact factor: 2.673

3.  Cyanidin-3-O-Glucoside Ameliorates Lipopolysaccharide-Induced Injury Both In Vivo and In Vitro Suppression of NF-κB and MAPK Pathways.

Authors:  Ming-Ming Ma; Yan Li; Xiang-Yong Liu; Wei-Wei Zhu; Xiang Ren; Gui-Qing Kong; Xiao Huang; Li-Peng Wang; Li-Qing Luo; Xiao-Zhi Wang
Journal:  Inflammation       Date:  2015-08       Impact factor: 4.092

4.  The peptide lycosin-I attenuates TNF-α-induced inflammation in human umbilical vein endothelial cells via IκB/NF-κB signaling pathway.

Authors:  Xianyao Li; Yaqin Tang; Binbin Ma; Zheng Wang; Jinying Jiang; Shengjie Hou; Shuhang Wang; Jie Zhang; Meichun Deng; Zhigui Duan; Xing Tang; Alex F Chen; Liping Jiang
Journal:  Inflamm Res       Date:  2018-03-10       Impact factor: 4.575

5.  Protocatechuic Acid Inhibits Inflammatory Responses in LPS-Stimulated BV2 Microglia via NF-κB and MAPKs Signaling Pathways.

Authors:  Huan-Yu Wang; Hong Wang; Jin-Huan Wang; Qiong Wang; Quan-Feng Ma; Yi-Yang Chen
Journal:  Neurochem Res       Date:  2015-07-02       Impact factor: 3.996

6.  7-Dehydrocholesterol (7-DHC), But Not Cholesterol, Causes Suppression of Canonical TGF-β Signaling and Is Likely Involved in the Development of Atherosclerotic Cardiovascular Disease (ASCVD).

Authors:  Shuan Shian Huang; I-Hua Liu; Chun-Lin Chen; Jia-Ming Chang; Frank E Johnson; Jung San Huang
Journal:  J Cell Biochem       Date:  2016-12-13       Impact factor: 4.429

7.  Oxymatrine lightened the inflammatory response of LPS-induced mastitis in mice through affecting NF-κB and MAPKs signaling pathways.

Authors:  Zhengtao Yang; Ronglan Yin; Yunfeng Cong; Zhanqing Yang; Ershun Zhou; Zhengkai Wei; Zhicheng Liu; Yongguo Cao; Naisheng Zhang
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092

Review 8.  The Impact of Anthocyanins and Iridoids on Transcription Factors Crucial for Lipid and Cholesterol Homeostasis.

Authors:  Maciej Danielewski; Agnieszka Matuszewska; Adam Szeląg; Tomasz Sozański
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 5.923

9.  Alpinetin attenuates inflammatory responses by suppressing TLR4 and NLRP3 signaling pathways in DSS-induced acute colitis.

Authors:  Xuexiu He; Zhengkai Wei; Jingjing Wang; Jinhua Kou; Weijian Liu; Yunhe Fu; Zhengtao Yang
Journal:  Sci Rep       Date:  2016-06-20       Impact factor: 4.379

10.  Saikosaponin A inhibits IL-1β-induced inflammatory mediators in human osteoarthritis chondrocytes by activating LXRα.

Authors:  Hang Gao; Yanyan Song; Dongsong Li; Wei Feng; Jianguo Liu
Journal:  Oncotarget       Date:  2017-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.